uz
Feedback
๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Kanalga Telegramโ€™da oโ€˜tish

ุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2bot

Ko'proq ko'rsatish

๐Ÿ“ˆ Telegram kanali ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ analitikasi

๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ (@aronstudy) Arab til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 13 242 obunachidan iborat bo'lib, Tibbiyot toifasida 1 944-o'rinni va Saudiya Arabistoni mintaqasida 5 753-o'rinni egallagan.

๐Ÿ“Š Auditoriya koโ€˜rsatkichlari va dinamika

ะฝะตะฒั–ะดะพะผะพ sanasidan buyon loyiha tez oโ€˜sib, 13 242 obunachiga ega boโ€˜ldi.

03 Iyul, 2026 dagi oxirgi maโ€™lumotlarga koโ€˜ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 94 ga, soโ€˜nggi 24 soatda esa -20 ga oโ€˜zgardi va umumiy qamrov yuqori darajada qolmoqda.

  • Tasdiqlash holati: Tasdiqlanmagan
  • Jalb etish (ER): Auditoriya oโ€˜rtacha 28.53% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining 7.27% ini tashkil etuvchi reaksiyalarni toโ€˜playdi.
  • Post qamrovi: Har bir post oโ€˜rtacha 3 779 marta koโ€˜riladi; birinchi sutkada odatda 963 ta koโ€˜rish yigโ€˜iladi.
  • Reaksiyalar va oโ€˜zaro taโ€™sir: Auditoriya faol: har bir postga oโ€˜rtacha 37 ta reaksiya keladi.
  • Tematik yoโ€˜nalishlar: Kontent ู…ูŽุงุฏูŽู‘ุฉ, ุทูŽุงู„ูุจ, ุงูุณุชูุจููŠูŽุงู†, ุณูŽู„ูŽุงู…, ุฑูุณูŽุงู„ูŽุฉ kabi asosiy mavzularga jamlangan.

๐Ÿ“ Tavsif va kontent siyosati

Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida taโ€™riflaydi:
โ€œุจุณู… ุงู„ู„ู‡ ุงู„ุฑุญู…ู† ุงู„ุฑุญูŠู… ุงู„ู„ู‡ู… ุตู„ ุนู„ู‰ ู…ุญู…ุฏ ูˆุขู„ ู…ุญู…ุฏ ู…ุญุชูˆู‰ ุงู„ู‚ู†ุงุฉ: ุดุฑูˆุญุงุช ุตูŠุฏู„ุฉ ุนุถูˆูŠุฉ ู…ุฑุญู„ุฉ ุซุงู†ูŠุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุซุงู„ุซุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุงูˆู„ ูุงุฑู…ุง ู…ุฑุญู„ุฉ ุฑุงุจุนุฉ ูƒูˆุฑุณ ุซุงู†ูŠ ุนู„ุงุฌูŠุงุช ู…ุฑุญู„ุฉ ุฎุงู…ุณุฉ ู„ู„ุชูˆุงุตู„: @AronX2botโ€

Yuqori yangilanish chastotasi (oxirgi maโ€™lumot 04 Iyul, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli boโ€˜lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim taโ€™sir nuqtasiga aylantirishini koโ€˜rsatadi.

13 242
Obunachilar
-2024 soatlar
-1437 kunlar
+9430 kunlar
Postlar arxiv
All of the following statements regarding type 1 diabetes are true EXCEPT: A. It is characterized by absolute lack of insulin B. It mostly afflict children C. ฮ’-cell destruction is attributed to autoimmune processes D. Genetic prediposition is very strong E. Ketoacidosis is mostly encountered in type 1 diabetes

A 13-year-old boy with type 1 diabetes is brought to the hospital complaining of dizziness. Laboratory findings include severe hyperglycemia, ketoacidosis, and a blood pH of 7.15. Which of the following agents should be administered to achieve rapid control of the severe ketoacidosis in this diabetic boy? A. Crystalline zinc insulin B. Glyburide C. Insulin glargine D. NPH insulin E. Insulin degludec

Regarding Neutral Protamine Hagedorm (NPH) insulin, which of the following statements is not correct: A. It is formed by the addition of zinc and protamine to regular insulin B. Less solubility and delayed absorption contributes to its longer duration of action C. It is used to control post-prandial glucose levels D. Its other name is insulin isophane E. It is not suitable for rapid lowering of glucose levels

BN is a patient with type 2 diabetes who has a blood glucose of 350 mg/dL today at his office visit. The physician would like to give some insulin to bring the glucose down before he leaves the office. Which of the following would is unappropriate for rapid lowering of blood glucose level in BN? A. Insulin aspart B. Insulin glargine C. Insulin glulisine D. Regular insulin E. Insulin lispro

Which of the following is an intermediate acting insulin that is formed by the addition of zinc and protamine to regular insulin? A. Insulin glargine B. Insulin detemir C. Aspart insulin D. Insulin isophane E. None of the above It's easy

A 72-year-old postmenopausal woman with severe osteoporosis and a recent history of vertebral fracture presents for treatment. She has chronic kidney disease. Which of the following is the most appropriate pharmacologic therapy for this patient? A) Alendronate B) Risedronate C) Zoledronic acid D) Denosumab Hmena, And why

A 70-year-old postmenopausal woman was recently diagnosed with osteoporosis. She has a history of esophagitis. What is the most appropriate pharmacologic treatment? A) Alendronate B) Risedronate C) Zoledronic acid D) Denosumab And why

ุจุงู„ุฑุณุงู„ุฉ ุงู„ู…ุซุจุชุฉ ู‡ูˆุงูŠ ุดุบู„ุงุช
+1
ุจุงู„ุฑุณุงู„ุฉ ุงู„ู…ุซุจุชุฉ ู‡ูˆุงูŠ ุดุบู„ุงุช

ุดุจุงุจ ุงุฐุง ุนุฏูƒู… ุงุณุฆู„ุฉ ุงู…ุชุญุงู† ุดุงู…ู„ ุงูˆ ู…ุฏ (ูุงุฑู…ุง) ุชุญุฏูŠุฏุง ู‡ุงูŠ ุงู„ุณู†ุฉ ุจุณ ูƒูˆู† ุจูŠู‡ุง ูƒูŠุณุงุช ู†ุณุชูุงุฏ ู…ู†ู‡ู† ุฏุฒูˆู„ูŠ ุนุงู„ุจูˆุช @Aron2bot

A 60-year-old man with osteoarthritis requires chronic therapy with NSAIDs. Which of the following prostaglandin agents can be added to his NSAID therapy to protect the GI mucosal lining and reduce the risk of gastric ulcers? A. Misoprostol B. Epoprostenol C. Bimatoprost D. Alprostadil ุงูƒูŠุฏ ุชุนุฑููˆู† ุงู„ุฌูˆุงุจ ุนู…ูˆู…ุง ู‡ุฐู†ูŠ ุงู„ุงุฎุชูŠุงุฑุงุช ูƒู„ู‡ู† ุนุจุงุฑุฉ PG analog ู„ูƒู†
Misoprostol PGE1 analog ูŠุณุชุฎุฏู… ู„ุญู…ุงูŠุฉ ุงู„ุฌู‡ุงุฒ ุงู„ู‡ุถู…ูŠ ู…ู† ุฎู„ุงู„ ุชู‚ู„ูŠู„ ุงูุฑุงุฒ ุญุงู…ุถ ุงู„ู…ุนุฏุฉ ูˆ ุฒูŠุงุฏุฉ ุชุตู†ูŠุน ุงู„ gastric mucus ุจู†ูุณ ุงู„ูˆู‚ุช ู‡ูˆ ูŠุญูุฒ ุชู‚ู„ุตุงุช ุจุงู„ุฑุญู… ูˆุจุงู„ุชุงู„ูŠ ู…ู…ูƒู† ูŠุณุจุจ ุงุฌู‡ุงุถ
Epoprostenol PGI2 analog ูŠุณุชุฎุฏู… ููŠ ู…ุนุงู„ุฌุฉ pulmonary hypertension
Bimatoprost PG2alpha analog ูŠุณุชุฎุฏู… ููŠ ู…ุนุงู„ุฌุฉ open angle glaucoma ูˆูŠุณุชุฎุฏู… ู„ุงุทุงู„ุฉ ุงู„ุฑู…ูˆุด ู„ู„ู†ุงุณ ุงู„ูŠ ูŠุนุงู†ูˆู† ู…ู† hypotrichosis
Alprostadil PGE1 analog ุจุณ ู‡ุฐุง ุงุณุชุฎุฏุงู…ู‡ ุฎุงุต ู„ุญุงู„ุฉductus arteriosus in neonates ูˆูŠุณุชุฎุฏู… ุจุญุงู„ุฉ ุงู„ erectile dysfunction
ู…ู† ุงุณุฆู„ุฉ ุงู„ู…ุตุฏุฑ ูˆู…ูˆุฌูˆุฏ ุนุฏูƒู… ุงู„ Misoprostol ุจุณ ุฎุงู ูŠุญูˆุฑ ุจุงู„ุณุคุงู„ ุนุงู„ุงู‚ู„ ุนุฏูƒู… ููƒุฑุฉ ุจุณูŠุทุฉ ุนู† ุงู„ุจู‚ูŠุฉ #NSAID ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

1. ุงุญู†ู‡ ู†ุนุฑู ุงู†ู‡ ุงู„ุงุณุจุฑูŠู† ูŠู…ุชู„ูƒ anti platlet effect ูˆู„ุฐู„ูƒ ูŠุณุชุฎุฏู… ู„ู„ูˆู‚ุงูŠุฉ ู…ู† ุชุฌู„ุท ุงู„ุฏู… ูƒู…ู…ูŠุน ู„ู„ุฏู… ุฒูŠู† ุงุฐุง ุงู†ุทูŠู†ู‡ ูˆูŠุงู‡ oral ant
1. ุงุญู†ู‡ ู†ุนุฑู ุงู†ู‡ ุงู„ุงุณุจุฑูŠู† ูŠู…ุชู„ูƒ anti platlet effect ูˆู„ุฐู„ูƒ ูŠุณุชุฎุฏู… ู„ู„ูˆู‚ุงูŠุฉ ู…ู† ุชุฌู„ุท ุงู„ุฏู… ูƒู…ู…ูŠุน ู„ู„ุฏู…
ุฒูŠู† ุงุฐุง ุงู†ุทูŠู†ู‡ ูˆูŠุงู‡ oral anticoagulants ู…ุซู„ ุงู„ warfarin ุงูˆ ุงู†ุทูŠู†ู‡ ูˆูŠุงู‡ parenteral anticoagulant ู…ุซู„ heparin ู‡ู†ุง ุฑุญ ูŠุฒุฏุงุฏ ุฎุทุฑ ุงู„ู†ุฒูŠู ุงู„ bleeding or hemorrhage
๏ปฟ 2. ู…ุฑุฉ ุซุงู†ูŠุฉ ุงุญู†ู‡ ู‡ู… ู†ุนุฑู ุงู†ู‡ ุงู„ุงุณุจุฑูŠู† ู‡ูˆ acid ุญุงู…ุถ ุนุถูˆูŠ ูŠู†ุทุฑุญ ุนู† ุทุฑูŠู‚ ู†ุงู‚ู„ ุงู„ู…ุดูƒู„ุฉ ุงู†ู‡ ุงู„ uric acid ู‡ู…ูŠู†ู‡ ุญุงู…ุถ ุนุถูˆูŠ ูŠู†ุทุฑุญ ุนู† ุทุฑูŠู‚ ู†ูุณ ุงู„ู†ุงู‚ู„
ู ุฑุญ ูŠุตูŠุฑ ุชู†ุงูุณ ุจูŠู† ุงู„ุงุณุจุฑูŠู† ูˆุงู„ uric acid ุนู„ู‰ ุงู„ู†ุงู‚ู„ ูˆูŠุซุจุท ุงูˆ ูŠู‚ู„ ุงุฎุฑุงุฌ ุงู„ uric acid ูˆูŠุฑุชูุน ุชุฑูƒูŠุฒู‡ ุจุงู„ุฏู… ูุดู†ูˆ ุญุงู„ ุงู„ูŠ ูŠุนุงู†ูŠ ู…ู† ุงู„ู€goutู€ู†ู‚ุฑุณ ุจู‡ุงูŠ ุงู„ุญุงู„ุฉุŸ ุงูƒูŠุฏ ุฑุญ ุชุชูุงู‚ู… ุญุงู„ุชู‡ ู†ูุณ ุงู„ุดูŠ ู„ุง ุชู†ุณูˆู† ุงูƒูˆ ุนู„ุงุฌ ู…ู† ุนู„ุงุฌุงุช ุงู„ู†ู‚ุฑุณ ุงุณู…ู‡ Probenecid ุขู„ูŠุฉ ุนู…ู„ู‡ ู‡ูŠ uricosuric drug ูŠุนู†ูŠ ูŠุนู…ู„ ุนู„ู‰ ุฒูŠุงุฏุฉ ุงุฎุฑุงุฌ ุงู„ uric acid ู…ู† ุฎู„ุงู„ ุชุซุจูŠุท ุงุนุงุฏุฉ ุงู…ุชุตุงุต ุงู„ uric acid ุทูŠุจ ุงุฐุง ุงู†ุทูŠุช ุงุณุจุฑูŠู† ูˆูŠุงู‡ ู‡ู…ูŠู†ู‡ ุงู„ุงุณุจุฑูŠู† ุฑุญ ูŠุชุฏุงุฎู„ ูˆูŠ ุนู…ู„ู‡ ูˆูŠุซุจุท ุงุฎุฑุงุฌ ุงู„ uric acid ูˆูŠุฑุชูุน ู…ุณุชูˆุงู‡ ุจุงู„ุฏู… ู„ุฐู„ูƒ ุงู„ุงุณุจุฑูŠู† ู…ู…ู†ูˆุน ู„ู…ุฑุถู‰ ุงู„ู†ู‚ุฑุณ gout
#NSAID ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุงู„ู…ุฌู…ูˆุนุฉ ุงู„ุฎุงู…ุณุฉ ุงุฏูˆูŠุฉ ุนุงุฆู„ุฉ ุงู„ Fenamates ูˆุชุชุถู…ู†: Mefenamic acid Meclofenamic acid
ุงู„ู…ุฌู…ูˆุนุฉ ุงู„ุงุฎูŠุฑุฉ ู‡ูŠ ุงู„ุงุฏูˆูŠุฉ ุงู„ูŠ ุชูƒูˆู† Selective Cox2 inhibitor ูˆุชุชุถู…ู†: Celecoxib ู…ูŠุฒุชู‡ุง ุงู‚ู„ ุชุฃุซูŠุฑ ุนู„ู‰ ุงู„ุฌู‡ุงุฒ ุงู„ู‡ุถู…ูŠ ู„ูƒู† ุณู„ุจูŠุชู‡ุง ุชุฒูŠุฏ ู…ุดุงูƒู„ ุงู„ู‚ู„ุจ ู…ุซู„ ุงู„ Myocardial infarction Stroke ู„ุฐู„ูƒ ู‡ุฐู‡ ุงู„ู…ุฌู…ูˆุนุฉ ู…ู…ู†ูˆุนุฉ ู„ู„ู…ุฑุถู‰ ุงู„ูŠ ูŠุนุงู†ูˆู† ู…ู† ุงู„ Cardiovascular events (ู…ู‡ู…)
#NSAID ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ุงู„ู…ุฌู…ูˆุนุฉ ุงู„ุซุงู„ุซุฉ ู‡ูŠ ุงู„ุงุฏูˆูŠุฉ ุงู„ู…ุดุชู‚ุฉ ู…ู† propionic acids ูˆุชุชุถู…ู† : Ibuprofen Fenoprofen Flurbiprofen Ketoprofen Naproxen Oxaprozin ู‡ุงูŠ ุงูƒุซุฑ ุงู„ NSAIDs ุงู…ุงู† ูˆู…ู‚ุจูˆู„ูŠุฉ ู…ู† ู‚ุจู„ ุงู„ู…ุฑุถู‰ุŒ ุจู…ุนู†ู‰ ุงู†ู‡ ุขุซุงุฑู‡ู‡ ุงู„ุฌุงู†ุจูŠุฉ ุงู‚ู„ ูˆุงู„ Naproxen ู‡ูˆ ุงู„ุนู„ุงุฌ ุงู„ุงูƒุซุฑ ุงู…ุงู†ุง ูˆู„ุฐู„ูƒ ู…ู…ูƒู† ุงุณุชุฎุฏุงู…ู‡ ููŠ ุงู„ู…ุฑุถู‰ ุงู„ูŠ ูŠุนุงู†ูˆู† ู…ู† Cardiovascular Events(ู…ู‡ู…)
๏ปฟ
ุงู„ู…ุฌู…ูˆุนุฉ ุงู„ุฑุงุจุนุฉ ู‡ูŠ ุงุฏูˆูŠุฉ ุนุงุฆู„ุฉ ุงู„ Oxicams ูˆุชุชุถู…ู† : Piroxicam Meloxicam ู‡ุงูŠ ุงู„ุงุฏูˆูŠุฉ ุจุงู„ุงุถุงูุฉ ุงู„ู‰ ุฏูˆุงุก ุงู„ sulindacุŒ ุชุชู…ูŠุฒ ุงู†ู‡ ุชู…ุชู„ูƒ ุงุทูˆู„ half life ู…ู† ู…ุฌู…ูˆุนุฉ ุงู„ NSAIDs ูƒูƒู„ (ู…ู‡ู…)
#NSAID ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ู…ุฎุทุท ู…ู‡ู… ูˆุฌุงูŠ ู…ู†ู‡ ุจุนุถ ุงู„ุงุณุฆู„ุฉ ุงู„ูˆุฒุงุฑูŠุฉ ุณุงุจู‚ุง ุงูˆู„ ู…ุฌู…ูˆุนุฉ ุงู„ salicylate ุงู„ู…ูƒูˆู†ุฉ ู…ู† Aspirin Salicylate salts Diflunisal ุงู„ุงุณุจุฑูŠู†
ู…ุฎุทุท ู…ู‡ู… ูˆุฌุงูŠ ู…ู†ู‡ ุจุนุถ ุงู„ุงุณุฆู„ุฉ ุงู„ูˆุฒุงุฑูŠุฉ ุณุงุจู‚ุง
ุงูˆู„ ู…ุฌู…ูˆุนุฉ ุงู„ salicylate ุงู„ู…ูƒูˆู†ุฉ ู…ู† Aspirin Salicylate salts Diflunisal ุงู„ุงุณุจุฑูŠู† ู…ุดุงูƒู„ู‡ ุงู„ุงุณุงุณูŠุฉ ุจุงู„ู…ุนุฏุฉ ู„ุฐู„ูƒ ูŠุณุจุจ upper Git disturbance ู…ู…ูƒู† ูŠุณุจุจ ulcer and bleeding(ู…ู‡ู…) ุจูŠู†ู…ุง ุงู„ Diflunisal ู…ูŠุฒู‡ ุงู†ู‡ ู…ุง ูŠู…ุชู„ูƒ ุชุฃุซูŠุฑุงุช ุฎุงูุถุฉ ู„ู„ุญุฑุงุฑุฉ ู…ุง ูŠู…ุชู„ูƒ antipyretic effect ูˆุชุฃุซูŠุฑุงุชู‡ ุนู„ู‰ ุงู„ู…ุนุฏุฉ ุงู‚ู„ ู…ู† ุงู„ุงุณุจุฑูŠู† (ู…ู‡ู…)
ุงู„ู…ุฌู…ูˆุนุฉ ุงู„ุซุงู†ูŠุฉ ู‡ูŠ ุงู„ุงุฏูˆูŠุฉ ุงู„ู…ุดุชู‚ุฉ ู…ู† ุงู„ acetic acids ุชุชุถู…ู†: Indomethacin Sulindac Tolmetin ู‡ุงูŠ ุงู„ุฅุฏูˆูŠุฉ ุฌุฏุง ู‚ูˆูŠุฉ ูˆู†ุณุชุนู…ู„ู‡ุง ููŠ ุญุงู„ุฉ ู…ุง ุญุตู„ู†ุง ูุนุงู„ูŠุฉ ู…ู† ุจุงู‚ูŠ ุงู„ุนู„ุงุฌุงุช ู…ุดูƒู„ุชู‡ุง ุงู„ุงุณุงุณูŠุฉ โ€ŒCNS Disturbance ูŠุณุจุจู† vertigo ูˆ dizzines ูˆ drowsiness ุฏูˆุงุฑ ูˆุฏูˆุฎุฉ ูˆู†ุนุงุณ ู„ุฐู„ูƒ ุงุฐุง ุงู„ู…ุฑูŠุถ ุจุญุงู„ุฉ ู‚ูŠุงุฏุฉ ู†ู†ุตุญู‡ ุจุนุฏู… ุงุณุชุฎุฏุงู… ู‡ุฐู‡ ุงู„ุฃุฏูˆูŠุฉ (ู…ู‡ู… ูˆุฒุงุฑูŠ ุฏูˆุฑ ุซุงู†ูŠ 2024)
#NSAID ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

Progesteron classification 1st Generation
Medroxiprogesterone Norethindrone
2nd Generation
Levonorgestrel Norgestrel
3rd Generation
Desogestrel Norgestimate Gestodene Etonogestrel
4th Generation
Dienogest Drospirenone
โญ•ุงู„ุฌูŠู„ ุงู„ุฃูˆู„ ูˆุงู„ุซุงู†ูŠ ูŠู…ุชู„ูƒูˆู† Androgenic Effects ู‚ูˆูŠุฉ ูˆุงู„ุงูƒุซุฑ ู‚ูˆุฉ ู‡ูˆ ุงู„ levonorgestrel ูˆู…ู† ุจุนุฏู‡ ุงู„ norgestrel ู…ุง ุฏุงู… ูŠู…ุชู„ูƒูˆู† ุชุฃุซูŠุฑ ุงู†ุฏุฑูˆุฌูŠู†ูŠ ู‚ูˆูŠ ูŠุนู†ูŠ ู…ู…ูƒู† ูŠุณุจุจูˆู† acne and hirsutism ุธู‡ูˆุฑ ุญุจ ุงู„ุดุจุงุจ ูˆู†ู…ูˆ ุงู„ุดุนุฑ ููŠ ุงู„ูˆุฌู‡
โญ•ุงู„ุฌูŠู„ ุงู„ุซุงู„ุซ ู„ุง ูŠู…ุชู„ูƒ ุชุฃุซูŠุฑ ุงู†ุฏุฑูˆุฌูŠู†ูŠ ุงูˆ ูŠู…ุชู„ูƒูˆู† ู„ูƒู† ุถุนูŠู ุฌุฏุง ูู†ุณุจุฉ ุญุตูˆู„ ุงู„ุงุซุงุฑ ุงู„ุฌุงู†ุจูŠุฉ ุงู„ acne and hirsutism ุฑุญ ุชูƒูˆู† ู‚ู„ูŠู„ุฉ ุฌุฏุง
โญ•ุงู„ุฌูŠู„ ุงู„ุฑุงุจุน ูŠู…ุชู„ูƒูˆู† anti androgenic effect ุชุฃุซูŠุฑุงุช ู…ุถุงุฏุฉ ู„ู„ุงู†ุฏุฑูˆุฌูŠู† ูˆู‡ู†ุง ุจุงู„ุนูƒุณ ู‡ุฐุง ุงู„ุฌูŠู„ ูŠู‚ู„ู„ ู…ู† ุธู‡ูˆุฑ ู‡ุฐู‡ ุงู„ุงุนุฑุงุถ
๏ปฟ #estrogen_progestin #contraceptive ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ

ู…ู„ุฎุต ุงู„estrogen https://t.me/Aronstudy/3278 ู…ู„ุฎุต ุงู„ Contraceptives https://t.me/Aronstudy/3283 ู…ู„ุฎุต ุงู„ adrenal gland https://t.me/Aronstudy/3261 ู…ู„ุฎุต pituitary Hormone https://t.me/Aronstudy/3285 ู…ู„ุฎุต Thyroid gland https://t.me/Aronstudy/3287 ุงุฐุง ุชู‚ุฑูˆู†ู‡ู† ูˆูŠ ุงู„ุดุฑุญ ูƒู„ุด ุฒูŠู†

ู‚ุงุฆู…ุฉ ุงู„ุดุฑุญ ูƒุงู…ู„ุฉ ุงู„# ุจูŠู‡ุง ู‡ูˆุงูŠ ู…ู„ุงุญุธุงุช ูˆู…ู„ุฎุตุงุช ุจุนุฏ ูƒู„ ุฌุงุจุชุฑ ุชุฎู„ุตูˆู†ู‡ ุญู„ูˆุง ูˆุฒุงุฑูŠุงุชู‡ ูˆุญู„ูˆุง ุงุณุฆู„ุฉ ุงู„ู…ุตุฏุฑ ู†ุณุฎุฉ ูง ูˆ ู†ุณุฎุฉ ูจ ู‡ู… ู„ุงู†
ู‚ุงุฆู…ุฉ ุงู„ุดุฑุญ ูƒุงู…ู„ุฉ
ุงู„# ุจูŠู‡ุง ู‡ูˆุงูŠ ู…ู„ุงุญุธุงุช ูˆู…ู„ุฎุตุงุช ุจุนุฏ ูƒู„ ุฌุงุจุชุฑ ุชุฎู„ุตูˆู†ู‡ ุญู„ูˆุง ูˆุฒุงุฑูŠุงุชู‡ ูˆุญู„ูˆุง ุงุณุฆู„ุฉ ุงู„ู…ุตุฏุฑ ู†ุณุฎุฉ ูง ูˆ ู†ุณุฎุฉ ูจ ู‡ู… ู„ุงู† ุจูŠู‡ุง ูƒูŠุณุงุช ู…ู‡ู…ุฉ ูƒู„ุดูŠ ู…ูˆุฌูˆุฏ ุจุงู„ู‚ุงุฆู…ุฉ โญ• ุญุงูˆู„ูˆ ู„ุง ุชุชุฑูƒูˆู† ุงูŠ ุฌุงุจุชุฑ ู‚ุฏุฑ ุงู„ุฅู…ูƒุงู† ูˆุงุฐุง ูƒู„ุด ุงู„ูŠ ุชุฑุฏูˆู† ุชุชุฑูƒูˆู†ู‡ ุงู‚ุฑูˆุง ุนู„ู‰ ู…ู„ุฎุต ุฏุฑุณูˆุง ู‚ุณู… ู‚ุณู… (ุงู„ุชู‡ุงุจุงุช ูˆ ุนุธุงู… ุŒ ุงู†ุฏูˆ ุŒ ูƒุงู†ุณุฑ) ุจุฃูŠ ุชุฑุชูŠุจ ุนุงุฏูŠ ุงู„ู…ู‡ู… ูƒู„ ู‚ุณู… ู„ูˆุญุฏู‡ ุงูŠ ุณุคุงู„ ุนุฏูƒู… ุณุฃู„ูˆุง ุงูŠ ุดูŠ ู…ุง ูุงู‡ู…ูŠู†ู‡ ุฏุฒูˆุง ูˆุงุดุฑุญู‡ ุงู„ูƒู… ู…ู† ุฌุฏูŠุฏ ูˆูŠุงูƒู… ู…ู†ุง ู„ู†ู‡ุงูŠุฉ ุงู„ุงู…ุชุญุงู† ุงู† ุดุงุก ุงู„ู„ู‡ ๐—”๐—ฅ๐—ข๐—ก ๐—ฆ๐—ง๐—จ๐——๐—ฌ